Since obstructive sleep apnea syndrome (OSAS) is often linked with systemic hypertension, we sought to clarify the characteristics ofprostanoid metabolism in OSAS. In 7 OSASpatients (apneahypopnea index, 51.0 ± 23.4) and 7 non-snorers as control, nocturnal urine was sampled and analyzed for stable metabolites of prostacyclin (PGI2) and thromboxane A2 (TxA2), [6-keto-PGFlot and thromboxane B2 (TxB2)]. The ratio of 6-keto-PGFl0C to TxB2 was significantly higher in OSAS (2.97 ± 1.52) than in control (1.38 ± 0.38). Successful treatment with nasal continuous positive airway pressure (8.3 ± 1.5 cmH2O)for 3 days caused a significant decrease in mean blood pressure in OSAS. Moreover, the 6-keto-PGFl0C to TxB2 ratio also significantly decreased to 1.74 ± 0.58, a level which may not significantly different from control. These results suggest that the production ratio of PGI2 to TxA2is shifted toward vasodilatation in untreated OSAS. Weconclude that the production of prostanoids plays a role in compensating for the systemic hypertension in OSAS.
Introduction
It is well recognized that thromboxane A2 (TxA2) is a vasoconstrictor as well as a potent stimulus for platelet aggregation which can be antagonized by the vasodilator prostacyclin (PGI2) (1) (2) (3) (4) (5) . It is also suggested thatthere is apathophysiological link between systemic hypertension and obstructive sleep apnea syndrome (OSAS) (6) (7) (8) . However, the role of the metabolism ofprostanoids in OSASremains elusive. Christman et al have reported that there is an increase in the 24-hour excretion of TxA2as well as a decrease in that of prostacyclin in the primary as well as in the secondary form of pulmonary hypertension (3) , suggesting that the imbalance in the release of these prostanoids is involved in the development and persistence of pulmonary hypertension.
Any stimulation of the arachidonate cascade such as via platelet activation potentially induces the increased vascular tone by TxA2in association with a decrease in the production of PGI2, resulting in pathologic stimulation coinciding with hypertension (9, 10) . Furthermore, OSASis accompanied by pulmonary hypertension and systemic hypertension in 1 0-20% (7, 1 1, 12) and 50-60% of all the cases (6) (7) (8) 13) , respectively. Accordingly, it may be of major importance to investigate the role of the arachidonate cascade pathwayand its enzymesas they are essentially involved in the maintenance of balance in the smooth muscle tone of the respiratory tract and in pulmonary vasculature. In the present study we investigated 1) whether the characteristics in the production of PGI2 and TxA2 during sleep are different in OSAScompared to control, and 2) how nasal continuous positive airway pressure (CPAP) influences prostanoid production and systemic blood pressure in OSAS.
Subjects and Methods

Subjects
Seven patients with OSASand 7 non-obese and non-snorer subjects as control subjects were investigated in the present study. Informed consent was obtained from all subjects. All of them were non-smokers and not taking nonsteroidal antiinflammatory or anti-hypertensive drugs. Mean age and body mass index (BMI) were 44 ± 12 (SD) years and 28.7 ± 4.3 kg/ m2 in OSAS, and 34 ± 4 years and 23.9 ± 6.4 kg/m2 in the control, respectively. In control, meanage and BMIwere not significantly different from OSAS (Table 1 ). All patients exhibited a moderate to severe degree of apnea-hypopnea index (AHI) from 21 to 86, andthe mean AHI was 51.0± 23.4. The ratios of oxygen desaturation time exhibiting arterial oxygen saturation (SaO2) less than 90% and 80% to total sleep time were 54.0 ± 35.5 and 29.3 ± 30.9%, respectively (Table 1) .
None of the OSASpatients was hypoxemic during wakefulness, and 2 of them were hypercapnic with partial pressure of carbon dioxide (PaCO2) of more than 45 mmHg. Systemic hypertension measured in the early morning, defined as systolic blood pressure higher than 160 mmHgor diastolic blood pressure higher than 95 mmHg,was observed in 4 of 7 OSAS patients. Onthe contrary, none of the control showedhypertension. Therefore, the meanarterial blood pressure was significantly higher in OSASthan in control (Table 1 ).
Sleep study protocol In patients with OSAS,nocturnal urine was sampled according to the manner described below. Blood pressure was measured with 24-hour monitoring by automated ambulatory blood pressure monitor (ABPM) including the first night. During the second night, sleep study was performed without nasal CPAP. For the third night, an appropriate level of nasal CPAP(CPAP Model 7100, Healthdyne Technologies, Marietta, GA, USA) was determined during the sleep study so as to maintain lowest SaO2 at more than 90%during non-rapid eye movement (NREM) and at 85% during rapid eye movement (REM) sleep, and these levels were also kept during the fourth night. At the fifth night, i.e., the third night after starting the application of nasal CPAP, urinary sampling was again performed simultaneously with the monitoring of 24-hour arterial blood pressure.
Urinary sampling and analysis
OSASpatients were asked to fully micturate at midnight and after that urine samples were collected during the period until 6 am if provided, and again taken at 6 am from all patients (6 hour after total micturition). Urine volume for 6-hour, and urinary concentrations of the stable metabolites of PGI2and TxA2, [6-keto- The effects of nasal CPAPon AHI, on O2 desaturation, as well as mean arterial blood pressure taken at 6 am in a supine position were compared before and 3 days after its start (Fig. 1 ). Effects of nasal CPAPon 24-hour blood pressure monitoring For the purpose of evaluating the effect of nasal CPAPon the time course of 24-hour blood pressure, the mean arterial pressure level was plotted in terms of the differences from the mean values obtained just 1 hour before starting sleep (Fig. 2 ).
Without nasal CPAP, the daily profile of arterial blood pressure exhibited little change throughout a 24-hour period, i.e., a nondipper pattern was observed in OSASwithout nasal CPAP treatment. On the other hand, successive 3-night treatment by
CPAPcaused a dipper pattern tendency, i.e., blood pressure showed decreasing trends during the night, although not to a statistically significant degree.
Effects of nasal CPAPon the excretion rate ofprostanoids Nasal CPAPproduced a significant decrease in urine volume for 6 hour from 284 ± 119 to 210 ± 72 ml (p<0.05). Urinary concentrations of 6-keto-PGFl0C and TxB2 were not significantly changed by nasal CPAP, from 0.363 ± 0.152 to 0.281 ± 0.100 and from 0.134 ± 0.064 to 0.179 ± 0.079 ng/ml, respectively. Eventually, the excretion rate of 6-keto-PGFl0C per minute decreased at a borderline significance (p=0.053) to a 60% level ofthepre-CPAP value, from 283 ± 173 to 171 ± 106 pg/min by nasal CPAP. On the other hand, TxB2 excretion remained at almost the same level, 101 + 61 without nasal CPAP and 113 ± 79 pg/min with CPAP.
The balance in the excretion of urinary prostanoids, that is, the excretion ratio of 6-keto-PGFla to TxB2, was evaluated (Fig. 3) . The ratio of 6-keto-PGFloc to TxB2 in the urinary sample for 6 hour was significantly higher in the untreated OSAS patients (2.97 ± 1.52) than in the control (1.38 ± 0.38; p<0.05). Moreover, the ratio significantly decreased with nasal Figure 3 . Urinary excretion ratios of6-keto-PGFlato TxB2 before nasal CPAP treatment and 3 days after starting nasal CPAPin OSASand in the control. The ratio was significantly higher in the untreated OSASpatients than in control, and it decreased significantly by nasal CPAP. 6kPGFla/TxB2: the ratio of6-keto-PGFla to thromboxane B2, off CPAP: before nasal CPAPtreatment, on CPAP: 3 days after starting nasal CPAP. Each bar represents mean ± SD. Figure 4 . Correlation between CPAP-induced changes in sleep parameters and the percent changes in the 6-keto-PGFloc to TxB2 ratios by the application of nasal CPAP. A relatively high correlation was observed between the decrease in meanblood pressure and % 6-keto-PGFlo/TxB2 (r=0.62). % 6kPGFla/TxB2, the percent change in the ratio of6-keto-PGFl0C to thromboxane B2 by the application of nasal CPAP. AAHI: the magnitude of the improvement in apnea-hypopnea index before and 3 days after starting nasal CPAP. ASaO2 <90%/TST: the magnitude of the improvement ratio in oxygen desaturation time exhibiting SaO2 of less than 90% to total sleep time before and after nasal CPAP. AmBP:the magnitude of the decrease in mean blood pressure in the early morning before and after nasal CPAP.
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were plotted in Fig. 4 . The magnitudes of the improvement of AHI and O2 desaturation, and those of the decrease in mean blood pressure in the early morning were plotted against the percent changes in the 6-keto-PGFla to TxB2 ratios by the application of nasal CPAP(% 6kPGFl0C/TxB2). A relatively high correlation (r=0.62) was observed between the decrease in mean blood pressure and % 6-keto-PGFla/TxB2. On the other hand, the degrees of improvement in AHI and sleep oxygen desaturation were not correlated with the changes in prostanoid excretion.
Discussion
The present study demonstrates that the urinary excretion ratio of 6-keto-PGFl0C to TxB2 during sleep was significantly higher in untreated OSASthan in control subjects. Nevertheless, arterial blood pressure was higher in OSASthan control. Furthermore, the successful application of nasal CPAPsignificantly decreased this ratio in association with a tendency to lower arterial blood pressure. These results might imply that the overall function of the prostanoid metabolism play a role in producing vasodilation in untreated OSAS, i.e., the increased production of 6-keto-PGFloc to TxB2is not the cause of the raised blood pressure, but rather the result of it. So, it might be considered that the increase in the 6-keto-PGFla to TxB2 ratio indicates a kind of compensatoryreaction, suggesting that either the production ofPGI2 is more upregulated in OSASthan control, or that of TxB2 is more downregulated. Nasal CPAP caused a significant decrease in diastolic blood pressure but a less than significant decrease in systolic blood pressure, suggesting that nasal CPAPmore effectively influenced peripheral vascular tone rather than the overall cardiac function in the present study. It is conceivable that the compensatory reaction of prostanoids observed caused sufficient vasodilative action in the untreated condition, but this level may not have been the absolute maximumbecause CPAPseemed to produce further vasodilatation. In the present study, the changes in excretion levels of PGI2 and TxA2as calculated per minute did not reach significant differences. It is likely that the ratio represents a reliable index for evaluating the prostanoid balance independent of the urinary volume. This suggests that the imbalance in prostanoids is involved in the development and persistence of pulmonary hypertension. It is assumed that endothelial damage which is inevitably accompanied by remodeling or organic change causes a deterioration ofPGI2 production in patients with pulmonary hypertension, as the vascular beds in pulmonaryarteries and/or arterioles are considered to be the main sites producing PGI2 (1) (2) (3) (4) (5) . However, it has not been clearly determined whether pulmonary vascular beds responsible for the production of PGI2are functionally preserved or not in OSAS.Sheer stress in pulmonary vascular beds can be observed in various kinds of physiological and pathological situations such as hypoxic pulmonary vasoconstriction (HPV) and increased cardiac output. Hypoxia is generally knownto be a cause of pulmonary as well as systemic hypertension ( 1 6). An ineffective respiratory effort which causes a dramatic increase in the fluctuations of intrathoracic pressure during obstructive apnea also functions as a stimulus for PGI2 production in pulmonary vascular beds. These characteristic changes are especially recognized in association with negative pressure elicited during inspiratory efforts (17). Moreover, increase in cardiac output is also accompanied by accentuated intrathoracic pressure, both of which can influence pulmonary vessels via sheer stress. Increased sympathetic activity in assoInternal Medicine Vol. 37, No. 2 (February 1998) ciation with arousal response during sleep also can increase systemic blood pressure in normal subjects and OSASpatients (18) (19) (20) . Taking these various factors into account, it is likely that prostanoid production plays a compensatory role in preventing further increases in arterial blood pressure in OSAS.
It is conceivable that this compensatory mechanismmayact against the rise in pulmonary arterial pressure. In the present study, right cardiac catheterization was performed only in 2 of the 7 cases. Their mean pulmonary arterial pressure was 19 and 20 mmHg,and cardiac index by the thermodilution method was 2.71 and 2.90 //min/m2, both of which remained within the normal range. Therefore, we could not determine the contribution of pulmonary hypertension to the excretion ofprostanoids. Krieger et al claimed that the ratio of 6-keto PGFlot to TxB2was less in OSASthan in control, suggesting that vasoconstrictive actions are involved in OSAS(21). It is likely that the difference between Krieger' s results and the present results depends on the level of pulmonary hypertension, i.e., pulmonary artery pressure in our patients was lower than in Krieger's cases. It is also conceivable that the vascular endothelium in our study wasless deteriorated than in Krieger's, or the degree ofOSASwas more prominent, namely, the degree of fluctuation in thoracic pressure may effectively produce more PGI2 than in Krieger's study.
It is broadly recognized that the application of nasal CPAP stabilizes the quality of sleep architecture, and eliminates the intrathoracic pressure fluctuations in association with the improvement of SaO2 (22, 23) . This results in the elimination of arousal response. The excitation of sympathetic tone is considered to be less prominent with nasal CPAP treatment than without it (20). These beneficial effects of nasal CPAPseem to eliminate the compensating reaction of prostanoids in OSAS, resulting in a normalization of 6-keto-PGFla to TxB2 ratio. As for the cause of hypertension, several mechanismshave been proposed in OSAS. Somers et al clearly demonstrated that increased sympathetic activities are involved in hypertensive subjects, and that this is especially prominent during REMsleep (19) . The contribution of hypoxia was also proposed (16). On the contrary, an increase in atrial natriuretic peptides (ANP) during sleep was proposed as a kind of compensation ofOSAS, i.e., a protective mechanismagainst the development ofhypertension (24). There is evidence that prostanoid excretion decreases in the aged compared to the young (25). However, this would have no bearing on our study, as the subjects were matched in age.
Amongimmunosuppressant agents, cyclosporine-A is important in the prevention of rejection in the field of transplantation (26). However, cyclosporine-A is known to be associated with the occurrence of systemic hypertension and an increasing rate ofthromboemboliccomplications (27) . It wasalso reported that the chronic administration of cyclosporine-A increased the TxA2 to PGI2 ratio (28), and that it diminished the production ofPGI2 in several vascular models (28). The effects ofTxA2on blood pressure have also been reported in animal experiments, where increased production of TxA2takes part in the systemic blood pressure regulation in spontaneously hypertensive rats (9) and Lyonstrain rats (10) , which also suggests that the ratio of PGI2 to TxA2 can be considered as an index of vasodilating activities from the viewpoint of prostanoid metabolism.
Prostanoids are cyclooxygenase metabolites of arachidonic acid and are considered to be one of the regulatory factors maintaining homeostasis that is closely related to endothelial function (29). It has been elucidated that the functional roles of the endothelium mainly include (a) activation and inhibition of circulating and local vasoactive hormones, (b) producing substances involved in coagulation, and (c) synthesizing and releasing vasoactive substances; PGI2and nitric oxide act as vasodilators and platelet function inhibitors whereas TxA2and endothelin are vasoconstrictor substances. Endothelium-derived relaxing substances predominantly appear to function under physiological conditions (30). In contrast, in the hypertensive and atherosclerotic arteries, the release of relaxing substances or the responsiveness of vascular smooth muscle cells to them is reduced while the release of endotheliumderived constricting factors is augmented, suggesting that the imbalance between relaxing and constricting substances plays a role, at least in part, in the pathogenesis of hypertension (29, 30) .
It has been reported that impaired vascular PGI2 generation and enhanced TxA2production occur in Dahl genetic strain rats susceptible to salt-induced hypertension (Dahl S) with borderline hypertension (3 1). However, both vascular PGI2 and vascular PGI2synthase activity are increased in accordance with blood pressure elevation in this model, which contribute to the restoration of vascular capacity to generate PGI2, suggesting that high blood pressure is a potential activator of vascular PGI2 synthase. Moreover, since PGI2 synthase activity is unaltered in Dahl S rats with borderline hypertension, the impaired PGI2 generation might be due to a decrease in arachidonate liberation or a lowered conversion of arachidonate to PGH2(32). These findings seem to imply that the enhanced PGI2generation and the increased PGI2 synthase are beneficial in treating high blood pressure and in protecting against the subsequent vascular wall damagein this animal model. Taking the evidence mentioned above into account, in the present study, it is likely that the relatively enhanced PGI2 production observed in OSASalso represents the beneficial effects on blood pressure regulation. It seems important that nasal CPAPproduced at least a tendency of a negative correlation between the degree of change in the ratio of PGI2 to TxA2 and the magnitude of decrease in blood pressure. This implies that the more the blood pressure is lowered, the more the PGI2to TxA2ratio will be decreased in OSASpatients. More patients will have to be investigated to confirm these results, because the effect of lowering blood pressure must depend on the untreated level of baseline blood pressure.
From the present study, we are led to believe that the production ratio of prostacyclin to thromboxane might be one of the key determinants in the susceptibility for nocturnal hypertension in patients with OSAS. Moreover, it is likely that there is somerelationship between the effectiveness of nasal CPAPon the decrease in production of the elevated prostacyclin 132 to TxB2 ratio and the decrease in mean blood pressure. These correlations lend support to the hypothesis that patients who develop hypertension are those in whomthe protective mechanism of prostacyclin release has failed. Furthermore, a valid interpretation might be that some OSASpatients excessively produce PGI2 in response to elevated blood pressure during the night because an excess amount of PGI2 is no longer needed once the elevated blood pressure is improved by CPAPtreatment. However, we cannot sufficiently explain whythe present data differed from that of Krieger et al (21) . To clarify these issues, further studies with greater numbers of subjects will need to be performed, although collecting a sufficient number of OSASpatients who had been free of nonsteroidal antiinflammatory and anti-hypertensive drugs may pose a problem.
In conclusion, the present data suggest that the relative levels ofPGI2 to TxA2were shifted toward vasodilatation in untreated OSAS.Therefore, it is concluded that the production of prostanoids plays a part in compensating for systemic hypertension in OSAS.This result is essentially different from that in the primary and secondary forms of pulmonary hypertension.
